Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

Clinical trial NCT07486687 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07486687
Sponsor: The Netherlands Cancer Institute
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC), Early Setting Early Stage Triple-Negative Breast Carcinoma Triple -Negative Breast Cancer Breast Cancer Stage II Breast Cancer Stage III

Start date: 2026-04-01
Primary completion: 2032-04-01
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.